Symetryx Corp's Form 4 filing
NeuBase Therapeutics, Inc. (NBSE) · filed Sep 11, 2023
- Accession no.
- 0001991925-23-000003
- Filed
- Sep 11, 2023
- Trade date
- Sep 7-11, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $336.7K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Symetryx CorpCIK 0001991925 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 7, 2023 | Common Stock, Par Value $0.0001 per Share | SSaleDisposed | −74,852 | $1.80 | −$134,733.6 | 605,149 | Direct | |
| Sep 8, 2023 | Common Stock, Par Value $0.0001 per Share | SSaleDisposed | −128,847 | $1.53 | −$197,135.91 | 476,302 | Direct | |
| Sep 11, 2023 | Common Stock, Par Value $0.0001 per Share | SSaleDisposed | −3,376 | $1.44 | −$4,861.44 | 472,926 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.